ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Infect Dis Ther,
  • DOI: 10.4172/2332-0877.1000495

The Combination of Aluminum Adjuvant and CpG Adjuvant can Enhance the Immunogenicity of Recombinant HPV Vaccines

Jun Ge1, Xiuying Pu2, Juyin Li3, Xiaoyu Xia2, Xiao Dong Wang1, Jiaojiao Sun1, Changyao Tan1, Tong Zhou1, Jianhui Zhang1, Srikanth Babu BMV1, Bao Mengru1, Xuan Liang1 and Jianqiang Li1*
1Department of Research and Development , Grand Theravac Life Sciences (Nanjing) Co. Ltd., Nanjing, China
2Department of Life Sciences, Lanzhou University of Technology, Lanzhou, China
3Department of Life Sciences, Jiangsu Argi-Animal Husbandry Vocational College, Jiangsu Province, China
*Corresponding Author : Jianqiang Li, Department of Research and Development , Grand Theravac Life Sciences (Nanjing) Co. Ltd., Nanjing, China, Tel: +86 13951080893, Email: lijianqiang@theravac.cn

Received Date: Apr 06, 2022 / Published Date: May 06, 2022

Abstract

Prophylactic vaccination and early detection of cervical cancers can effectively prevent Human Papilloma Virus (HPV) infection. HPV major capsid protein (HPV L1), a coat protein assembles into Virus-Like Particles (VLPs), acts as a potent immunogen. In the present investigational study, we evaluated the role of the combination effect of the aluminum adjuvant and TLR-9 agonist Cytosine phosphoguanine (CpG) on the immune response and the antigen dose-sparing effect.

HPV L1 VLPs for types 16/18/52 and 58 have been produced by a gene expressed in Hansenula polymorpha. Bivalent (16,18) and tetravalent (16,18,52,58) vaccines with mono (Al+) and biadjuvanted (Al+CpG) were formulated by adsorbing purified VLPs onto aluminum hydroxide and CpG. Sera collected from immunized BALB/c mice showed that biadjuvanted vaccines elicits significantly higher anti-HPV neutralizing antibodies than monoadjuvanted vaccines. Full-dose biadjuvant vaccines (4 μg) elicits 2.5 times higher neutralizing antibodies than half-dose vaccine and no significant differences were observed between the full-dose monoadjuvant vaccine (Al+) and the half-dose biadjuvant vaccine (Al+CpG). Immunised mice have distinct levels of secreted IgG antibodies and the vaccines formulated with a aluminium and CpG, a TLR-9 agonist had skewed towards high Th1 biased immune response with an elevated IgG2a/IgG1 ratio.

In conclusion, recombinant HPV vaccines formulated with an immune modulating CpG agonist and an adjuvant can induce a greater immune response. This combination of CpG and alum effectively reduces the dose of the HPV L1 vaccine by 2.5 times and makes the availability of vaccines at an affordable price.

Keywords: Cervical cancer; Human papilloma virus; Virus like particles; CpG adjuvant; Biadjuvanted vaccines; Antigen dose sparing

Citation: Ge J, Pu X, Li J, Xia X, Wang XD, et al. (2022) The Combination of Aluminum Adjuvant and CpG Adjuvant can Enhance the Immunogenicity of Recombinant HPV Vaccines. J Infect Dis Ther 10: 495. Doi: 10.4172/2332-0877.1000495

Copyright: © 2022 Ge J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top